PALO ALTO, Calif., Oct. 7, 2019 /PRNewswire/ -- Kodiak Sciences Inc.
(Nasdaq: KOD), a clinical stage biopharmaceutical company
specializing in novel therapeutics to treat chronic,
high-prevalence retinal diseases, today announced that Charles C. Wykoff, M.D., Ph.D., will present
first-time results at the Annual Meeting of the American Academy of
Ophthalmology (AAO) to be held in San
Francisco, California. The Retina Subspecialty Day
(October 11 – 12) will feature a
presentation of emerging data from the Phase 1b clinical study of KSI-301 in treatment-naïve
patients with neovascular age-related macular degeneration (wet
AMD), Diabetic Macular Edema (DME), and Retinal Vein Occlusion
(RVO).
"We were very pleased with the early durability data from
patients with wet AMD treated with KSI-301 in our Phase
1b clinical study announced last
month at The Retina Society Annual Meeting. Those data underscored
our belief in the potential for KSI-301 to be a leading,
next-generation anti-VEGF with a long-interval durability profile,"
said Victor Perlroth, M.D., Chief
Executive Officer of Kodiak Sciences. "We look forward to building
on those initial results with Dr. Charles
Wykoff's upcoming presentation at the AAO Retina
Subspecialty Day, where new data will be shown on the efficacy,
safety and durability of KSI-301 in wet AMD as well as DME and RVO.
These are the three diseases most commonly treated with
intravitreal anti-VEGF therapies. We look forward to further
engaging with the community about the new data and our planning for
the clinical development of KSI-301."
Details of the presentation are as follows:
Oral Presentation: Extended Durability in Exudative
Retinal Diseases Using the Novel Intravitreal Anti-VEGF Antibody
Biopolymer Conjugate KSI-301: Results from the Phase 1b Study in Patients with wAMD, DME and RVO
Presenter: Charles C. Wykoff, M.D., Ph.D. – Retina
Consultants of Houston,
Houston, TX
Presentation date and time: Friday, October 11, 2019 –
4:58pm PT
The slide presentation will be available on the Kodiak Investor
Relations website at http://ir.kodiak.com/ at the time of the
presentation.
About KSI-301
KSI-301 is an investigational therapy built on the Company's ABC
Platform and is designed to maintain potent and effective drug
levels in ocular tissues for longer than existing agents. Kodiak's
objective with KSI-301 is to develop a new first-line agent to
improve outcomes for patients with retinal vascular diseases and to
enable earlier treatment and prevention of vision loss for patients
with diabetic eye disease. KSI-301 is being developed and is fully
owned globally by Kodiak Sciences Inc.
About Kodiak Sciences Inc.
Kodiak™ is a clinical-stage biopharmaceutical company
specializing in novel therapeutics to treat chronic,
high-prevalence retinal diseases. We are focused on bringing new
science to the design and manufacture of next generation retinal
medicines to prevent and treat the leading causes of blindness
globally. Our ABC Platform™ merges the fields of antibody-based and
chemistry-based therapies and is at the core of Kodiak's discovery
engine. Kodiak's lead product candidate, KSI-301, is a novel
anti-VEGF antibody biopolymer conjugate being developed for the
treatment of retinal vascular diseases including age-related
macular degeneration and diabetic eye diseases. Kodiak has
leveraged its ABC Platform to build a pipeline of product
candidates in various stages of development including KSI-501, our
bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of
neovascular retinal diseases with an inflammatory component. Kodiak
is based in Palo Alto, CA. For
more information, visit www.kodiak.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
not based on historical fact and include statements regarding our
platform technology and potential therapies, future development
plans, clinical and regulatory objectives and the timing thereof,
anticipated design of planned clinical trials, expectations
regarding the potential efficacy and commercial potential of our
product candidates, including KSI-301, the anticipated presentation
of data, the results of our research and development efforts and
our ability to advance our product candidates into later stages of
development. Forward-looking statements generally include
statements that are predictive in nature and depend upon or refer
to future events or conditions, and include words such as "may,"
"will," "should," "would," "expect," "plan," "believe," "intend,"
"pursue," and other similar expressions among others. Any
forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to, the preliminary safety, efficacy and
durability data for our KSI-301 product candidate from the Phase 1
study will not continue or persist; cessation or delay of any of
the ongoing clinical studies and/or our development of KSI-301 may
occur; future potential regulatory milestones of KSI-301, including
those related to current and planned clinical studies may be
insufficient to support regulatory submissions or approval;
anticipated presentation of data at upcoming conferences may not
occur; our research and development efforts and our ability to
advance our product candidates into later stages of development may
fail; any one or more of our product candidates may not be
successfully developed, approved or commercialized; adverse
conditions in the general domestic and global economic markets; as
well as the other risks identified in our filings with the
Securities and Exchange Commission. For a discussion of other risks
and uncertainties, and other important factors, any of which could
cause our actual results to differ from those contained in the
forward-looking statements, see the section entitled "Risk Factors"
in our most recent Form 10-Q, as well as discussions of potential
risks, uncertainties, and other important factors in our subsequent
filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof and
Kodiak undertakes no obligation to update forward-looking
statements, and readers are cautioned not to place undue reliance
on such forward-looking statements.
"Kodiak," "ABC Platform" and the Kodiak logo are registered
trademarks or trademarks of Kodiak Sciences Inc. in various
jurisdictions.
View original
content:http://www.prnewswire.com/news-releases/kodiak-sciences-announces-upcoming-presentation-of-durability-data-from-clinical-development-program-of-ksi-301-in-wet-amd-dme-and-rvo-at-american-academy-of-ophthalmology-2019-annual-meeting-300932761.html
SOURCE Kodiak Sciences Inc.